Show simple item record

dc.contributor.authorBroadley, Simonen_US
dc.contributor.authorBarnett, Michael H.en_US
dc.contributor.authorBoggild, Mikeen_US
dc.contributor.authorBrew, Bruce J.en_US
dc.contributor.authorButzkueven, Helmuten_US
dc.contributor.authorHeard, Roberten_US
dc.contributor.authorHodgkinson, Suzanneen_US
dc.contributor.authorKermode, Allan G.en_US
dc.contributor.authorLechner-Scott, Jeanetteen_US
dc.contributor.authorMacdonell, Richard A. L.en_US
dc.contributor.authorMarriott, Marken_US
dc.contributor.authorMason, Deborah F.en_US
dc.contributor.authorParratt, Johnen_US
dc.contributor.authorReddel, Stephen W.en_US
dc.contributor.authorShaw, Cameron P.en_US
dc.contributor.authorSlee, Marken_US
dc.contributor.authorSpies, Judith M.en_US
dc.contributor.authorTaylor, Bruce V.en_US
dc.contributor.authorCarroll, William M.en_US
dc.contributor.authorKilpatrick, Trevor J.en_US
dc.contributor.authorKing, Johnen_US
dc.contributor.authorMcCombe, Pamela Aen_US
dc.contributor.authorPollard, John D.en_US
dc.contributor.authorWilloughby, Ernesten_US
dc.date.accessioned2018-07-26T12:30:32Z
dc.date.available2018-07-26T12:30:32Z
dc.date.issued2015en_US
dc.identifier.issn0025-729Xen_US
dc.identifier.doi10.5694/mja14.01218en_US
dc.identifier.urihttp://hdl.handle.net/10072/141918
dc.description.abstract- Multiple sclerosis (MS) is an autoimmune disease of the central nervous system with a multifactorial aetiology and highly variable natural history. - A growing understanding of the immunopathogenesis of the condition has led to an expanding array of therapies for this previously untreatable disease. While a cure for MS remains elusive, the potential to reduce inflammatory disease activity by preventing relapses and minimising disease progression is achievable. - The importance of early treatment in minimising long-term disability is increasingly recognised. Most of the newer, more effective therapies are associated with risks and practical problems that necessitate an active management strategy and continuous vigilance. - While the initiation of these therapies is likely to remain the responsibility of neurologists, other specialist physicians and general practitioners will be involved in the identification and management of adverse effects.en_US
dc.description.peerreviewedYesen_US
dc.languageenglishen_US
dc.publisherAustralasian Medical Publishing Companyen_US
dc.relation.ispartofpagefrom139en_US
dc.relation.ispartofpageto141en_US
dc.relation.ispartofissue3en_US
dc.relation.ispartofjournalThe Medical Journal of Australiaen_US
dc.relation.ispartofvolume203en_US
dc.subject.fieldofresearchClinical Sciences not elsewhere classifieden_US
dc.subject.fieldofresearchcode110399en_US
dc.titleA new era in the treatment of multiple sclerosisen_US
dc.typeJournal articleen_US
dc.type.descriptionC1 - Peer Reviewed (HERDC)en_US
dc.type.codeC - Journal Articlesen_US
dc.description.versionPublisheden_US
gro.facultyGriffith Health, School of Medicineen_US
gro.rights.copyrightBroadley SA, Barnett MH, Boggild M, et al. A new era in the treatment of multiple sclerosis. Med J Aust 2015; 203 (3): 139-141. © Copyright 2015 The Medical Journal of Australia – reproduced with permission.en_US
gro.hasfulltextFull Text


Files in this item

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record